Exenatide (Byetta) Vs Pramlintide (Symlin): Role in Post-Prandial Hyperglycemia.

Trial Profile

Exenatide (Byetta) Vs Pramlintide (Symlin): Role in Post-Prandial Hyperglycemia.

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Exenatide (Primary) ; Pramlintide (Primary) ; Insulin
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jun 2017 Status changed from recruiting to completed, based on the results presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
    • 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
    • 08 Dec 2010 Additional lead trial centre/investigator identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top